Multiple Myeloma Clinical Trials

533 recruitingLast updated: June 17, 2026

There are 533 actively recruiting multiple myeloma clinical trials across 55 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Multiple Myeloma Trials at a Glance

533 actively recruiting trials for multiple myeloma are listed on ClinicalTrialsFinder across 6 cities in 55 countries. The largest study group is Phase 2 with 200 trials, with the heaviest enrollment activity in New York, Boston, and Atlanta. Lead sponsors running multiple myeloma studies include Institute of Hematology & Blood Diseases Hospital, China, Memorial Sloan Kettering Cancer Center, and Janssen Research & Development, LLC.

Browse multiple myeloma trials by phase

Treatments under study

About Multiple Myeloma Clinical Trials

Looking for clinical trials for Multiple Myeloma? There are currently 386 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Multiple Myeloma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 533 trials

Recruiting
Phase 4

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Multiple Myeloma
Pfizer80 enrolled33 locationsNCT06057402
Recruiting
Phase 3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 2

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Multiple Myeloma
Memorial Sloan Kettering Cancer Center26 enrolled7 locationsNCT07454382
Recruiting
Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled39 locationsNCT06140524
Recruiting
Phase 3

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
AbbVie380 enrolled166 locationsNCT06158841
Recruiting
Phase 1

Personalized Autologous Transplant for Multiple Myeloma

Multiple Myeloma
Emory University90 enrolled2 locationsNCT04483206
Recruiting
Phase 1

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Multiple MyelomaPlasma Cell Myeloma
Robert Flavell, MD, PhD20 enrolled1 locationNCT05892393
Recruiting
Phase 1

Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma

Newly Diagnosed Multiple Myeloma (NDMM)Multiple Myloma
The First Affiliated Hospital of Soochow University18 enrolled1 locationNCT07652138
Recruiting
Phase 3

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled116 locationsNCT07391657
Recruiting
Not Applicable

The Ambient Light Multiple Myeloma Study

Multiple Myeloma
Icahn School of Medicine at Mount Sinai200 enrolled2 locationsNCT05737732
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Multiple Myeloma
GlaxoSmithKline200 enrolled27 locationsNCT07227311
Recruiting
Phase 1

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma
Pfizer87 enrolled43 locationsNCT06215118
Recruiting
Phase 1

Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

Multiple Myeloma in RelapseMultiple Myeloma, Refractory
University Health Network, Toronto20 enrolled1 locationNCT07456605
Recruiting
Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 2Phase 3

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Multiple Myeloma
AbbVie660 enrolled49 locationsNCT07095452
Recruiting
Not Applicable

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

Multiple MyelomaComplication
Centre Leon Berard204 enrolled6 locationsNCT05947136
Recruiting
Phase 2

Horizon Two: HR NDMM (MMRC-100)

High Risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled7 locationsNCT07053436
Recruiting
Phase 3

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Multiple Myeloma
Pfizer1,116 enrolled111 locationsNCT05623020
Recruiting
Phase 3

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals270 enrolled1 locationNCT07393282
Recruiting
Phase 1

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory
Washington University School of Medicine52 enrolled1 locationNCT07200089